* The Board believes it can deliver more than $ 1.20 per share from net cash
assets less wind down costs, rights to approximately $ 6 million ($ 0.20 per share) of near - term Genzyme payments and the sale of AV411.
Not exact matches
According to this filing, MNOV proposes to offer AVGN stockholders a pro rata portion of 1.75 M shares of MNOV and a convertible security representing AVGN's «Net Cash
Assets,» which MNOV defines as AVGN's cash remaining after it is
wound up
less $ 7M paid to be paid to MNOV.
The remaining amount of Avigen cash after Avigen's
wind - up activities are completed and
less the $ 7 million in cash received by MediciNova (the «Net Cash
Assets») will be sequestered and, unless converted earlier as described in the next sentence, not used until the later of March 31, 2010 or 12 months from the closing of the merger transaction (the «Final Conversion Date»).
* The Board believes that the offer price of $ 1.20 per share is approximately the company's current net cash value
less wind down costs, but does not reflect the value for the company's other
assets, including its AV411 pain and addiction program and rights to future payments from Genzyme Corporation.